Strides Pharma Science Singapore arm secures USFDA nod for nonsteroidal anti-inflammatory drug
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-05-01 06:05 GMT | Update On 2025-05-01 06:05 GMT
Advertisement
Bangalore: Strides Pharma Global Pte. Limited, a step-down wholly owned subsidiary of Strides Pharma Science Limited in Singapore, has received approval from the United States Food & Drug Administration (USFDA) for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex Capsules, 100 mg, 200 mg, and 400 mg, of Upjohn US 2 LLC.
Celecoxib is a selective COX-2 inhibitor used for the management of pain and inflammation associated with various conditions including osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea. Celecoxib Capsules, 100 mg, 200 mg, and 400 mg have a combined market size of ~US$ 116 Mn as per IMS.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.